ClinicalTrials.gg
Not yet recruitingNCT07915297Updated Nov 4, 2026

Safety and Biodistribution of [68Ga]Ga DOTA-5G in Subjects With Metastatic Breast Cancer (BC)

A Phase 1 interventional study of [68Ga]Ga DOTA-5G in Metastatic Breast Cancer, sponsored by Luminance Biosciences Inc. Not yet recruiting at 1 site in Australia. Open to participants aged 18 Years to 89 Years. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Luminance Biosciences Inc · Phase 1, Interventional, and Diagnostic

Updated Nov 4, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years to 89 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 403 studies in Breast Neoplasms with a site in Australia — 85 open to participants now, 156 under way, 61 of them phase 3. Breast Neoplasms · Australia.

Planned enrollment
375th of 381
10 · median 252
Started
2026
with 16 others
Phase 1
72 of 403
23 open now
Primary completion
2027-12
later than 92 of 155 live
Registered
403rd of 403
by date

Among the 403 studies in Breast Neoplasms with a site in Australia, this one is the 375th largest by planned enrollment of the 381 interventional ones that give a count, is one of 17 that started in 2026, is one of 72 in phase 1, reaches primary completion later than 92 of the 155 other live ones, and was the 403rd registered.

Breast Neoplasms

14,840 studies on the registry are indexed under Breast Neoplasms; 3,319 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

85 of the 403 studies in Breast Neoplasms with a site in Australia are open now. Recruiting first, the newest first:

80 more — sign in →

All 85 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 2,398 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 590 (25%) stop at 75 or younger; 103 take children under 18; 213 take healthy volunteers.

This study: 18 Years to 89 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 403 studies in Breast Neoplasms with a site in Australia, or all of them as a file.
02

Study summary

This is a prospective study using [68Ga]Ga DOTA-5G PET/CT imaging in patients diagnosed with metastatic breast cancer (BC).

Read the detailed description

This is a phase I study that will investigate [68Ga]Ga DOTA-5G in patients with metastatic BC. 10 patients diagnosed with invasive BC will be enrolled.

03

Conditions studied

  • Metastatic Breast Cancer

Keywords

  • PET
  • Imaging
  • Diagnostic
  • Breast Cancer
04

Who can participate

Ages eligible
18 Years to 89 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ability to understand and willingness to sign a written document.
  • Men and women age ≥ 18 yrs
  • Confirmed presence of breast cancer
  • Performance Status ≤ 2
  • Hematologic parameters defined as:
  • (ANC) ≥ 1x 109 /L,
  • count ≥ 100x 109 /L,
  • ≥ 80 g/L.
  • Blood chemistry levels defined as:
  • , ALT, alkaline phosphatase ≤ 5 times (ULN),
  • Total ≤ 2 times ULN,
  • Creatinine ≤ 2 times ULN.
  • Anticipated ≥ 3 months
  • Able to remain motionless for up to 30-60 minutes per scan.

Exclusion criteria

Exclusion Criteria:

  • Pregnant and lactating women
  • Prisoners
  • Concurrent of a different histology that could confound imaging interpretation.
  • Patients who cannot undergo PET/CT scanning because of weight limits(>450lbs)
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    [68Ga]Ga DOTA-5G PET/CT imaging

    Drug: [68Ga]Ga DOTA-5G

Interventions

  • Patients will be injected with up to 5 mCi of \[68Ga\]Ga DOTA-5G and imaged at 1 and 2 hours post injection

06

What researchers measure

Primary outcomes

  1. The ability of [68Ga]Ga DOTA-5G PET/CT imaging to detect lesions

    To assess the ability of \[68Ga\]Ga DOTA-5G to detect lesions: detection of metastasis by \[68Ga\]Ga DOTA-5G , positive vs. negative based on if SUVmax above background brain, bone, lung, or liver of \[68Ga\]Ga DOTA-5G in at least one lesion assessed by \[68Ga\]Ga DOTA-5G PET/CT and identified on \[18F\]-FDG PET/CT diagnostic imaging.

    Time frame: 2 hours from time of injection

Secondary outcomes

  1. Safety and tolerability [68Ga]Ga DOTA-5G based on the incidence of of adverse events using CTCAE v5.0.

    To evaluate the Safety and tolerability \[68Ga\]Ga DOTA-5G patients will be followed for up to 7 days for AEs using CTCAE v5.0.

    Time frame: up to 7 days from time of injection

07

Study locations

1 site
  • Icon Cancer Center
    Nedlands, Washington 6009, Australia
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Dec 2027, 13 months later.

Of 389 industry-sponsored phase 1 interventional studies under Breast Neoplasms, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 56. This study's planned 13 months is below that.

Counting every sponsor, half of 762 studies reached it within 44 months; a quarter within 25 and three quarters within 65.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 29, 2026
First posted
Nov 4, 2026
StartEst.
Nov 15, 2026
Primary completionEst.
Dec 31, 2027
CompletionEst.
Jun 30, 2028
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07915297
Lead sponsor
Luminance Biosciences Inc
Collaborators
Icon Cancer Center Hollywood, Icon Group, Ace Integrated Consulting
Responsible party
Sponsor
First posted
Nov 4, 2026
Start date
Nov 15, 2026 (estimated)
Primary completion
Dec 31, 2027 (estimated)
Completion
Jun 30, 2028 (estimated)
Last update
Nov 4, 2026

Study contacts

Julie Sutcliffe, Ph.D
Contact
jlsutcliffe@luminancebio.com
5302048801
Julie Sutcliffe
study director · Luminance Biosciences Inc

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gallium-68

Start the discussion